215 related articles for article (PubMed ID: 37184779)
1. Mutational signatures for breast cancer diagnosis using artificial intelligence.
Odhiambo P; Okello H; Wakaanya A; Wekesa C; Okoth P
J Egypt Natl Canc Inst; 2023 May; 35(1):14. PubMed ID: 37184779
[TBL] [Abstract][Full Text] [Related]
2. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
4. [Hereditary breast carcinomas pathologist's perspective].
Vincent-Salomon A; Bataillon G; Djerroudi L
Ann Pathol; 2020 Apr; 40(2):78-84. PubMed ID: 32241645
[TBL] [Abstract][Full Text] [Related]
5. Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.
Bernstein-Molho R; Singer A; Laitman Y; Netzer I; Zalmanoviz S; Friedman E
Breast Cancer Res Treat; 2019 Jul; 176(1):165-170. PubMed ID: 30980208
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
[TBL] [Abstract][Full Text] [Related]
7. Network-based approaches elucidate differences within APOBEC and clock-like signatures in breast cancer.
Kim YA; Wojtowicz D; Sarto Basso R; Sason I; Robinson W; Hochbaum DS; Leiserson MDM; Sharan R; Vadin F; Przytycka TM
Genome Med; 2020 May; 12(1):52. PubMed ID: 32471470
[TBL] [Abstract][Full Text] [Related]
8. Integrative genomic analysis identifies associations of molecular alterations to APOBEC and BRCA1/2 mutational signatures in breast cancer.
Trevino V
Mol Genet Genomic Med; 2019 Aug; 7(8):e810. PubMed ID: 31294536
[TBL] [Abstract][Full Text] [Related]
9. Mutational landscape differences between young-onset and older-onset breast cancer patients.
Mealey NE; O'Sullivan DE; Pader J; Ruan Y; Wang E; Quan ML; Brenner DR
BMC Cancer; 2020 Mar; 20(1):212. PubMed ID: 32164620
[TBL] [Abstract][Full Text] [Related]
10. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
Sung PL; Wen KC; Chen YJ; Chao TC; Tsai YF; Tseng LM; Qiu JT; Chao KC; Wu HH; Chuang CM; Wang PH; Huang CF
PLoS One; 2017; 12(9):e0185615. PubMed ID: 28961279
[TBL] [Abstract][Full Text] [Related]
11. Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants.
Lim BWX; Li N; Mahale S; McInerny S; Zethoven M; Rowley SM; Huynh J; Wang T; Lee JEA; Friedman M; Devereux L; Scott RJ; Sloan EK; James PA; Campbell IG
J Natl Cancer Inst; 2023 Feb; 115(2):181-189. PubMed ID: 36315097
[TBL] [Abstract][Full Text] [Related]
12. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
Kleibl Z; Kristensen VN
Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168
[TBL] [Abstract][Full Text] [Related]
13. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
[TBL] [Abstract][Full Text] [Related]
14. Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
Van Marcke C; Helaers R; De Leener A; Merhi A; Schoonjans CA; Ambroise J; Galant C; Delrée P; Rothé F; Bar I; Khoury E; Brouillard P; Canon JL; Vuylsteke P; Machiels JP; Berlière M; Limaye N; Vikkula M; Duhoux FP
Breast Cancer Res; 2020 Apr; 22(1):36. PubMed ID: 32295625
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
16. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns.
Sørensen SG; Shrikhande A; Poulsgaard GA; Christensen MH; Bertl J; Laursen BE; Hoffmann ER; Pedersen JS
Elife; 2023 Mar; 12():. PubMed ID: 36883553
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.
Thirthagiri E; Lee SY; Kang P; Lee DS; Toh GT; Selamat S; Yoon SY; Taib NA; Thong MK; Yip CH; Teo SH
Breast Cancer Res; 2008; 10(4):R59. PubMed ID: 18627636
[TBL] [Abstract][Full Text] [Related]
19. Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort.
Pipek O; Alpár D; Rusz O; Bödör C; Udvarnoki Z; Medgyes-Horváth A; Csabai I; Szállási Z; Madaras L; Kahán Z; Cserni G; Kővári B; Kulka J; Tőkés AM
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239898
[TBL] [Abstract][Full Text] [Related]
20. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.
Deb S; Wong SQ; Li J; Do H; Weiss J; Byrne D; Chakrabarti A; Bosma T; ; Fellowes A; Dobrovic A; Fox SB
Br J Cancer; 2014 Dec; 111(12):2351-60. PubMed ID: 25490678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
